NEW! The Gist (AUG-24) | E-BOOKS
(GIST OF SCIENCE REPORTER) Tirzepatide
(GIST OF SCIENCE REPORTER) Tirzepatide
(JULY-2024)
Tirzepatide
-
India is set to approve the weight-loss drug tirzepatide marking a significant advancement in obesity treatment.
-
This follows global trends where drugs like semaglutide (Ozempic and Wegovy) have shown dramatic weight loss effects.
-
Tirzepatide, originally approved for diabetes, also induces weight loss by boosting hormones GLP-1 and GIP, which promote satiety and manage glucose levels.
-
Clinical trials have demonstrated substantial weight loss with tirzepatide, with participants losing up to 20.9% of their body weight.
-
However, ongoing use is necessary to maintain these results, as stopping the medication leads to weight regain.
-
Side effects include nausea, vomiting, and risk of thyroid tumours.
CLICK HERE TO DOWNLOAD FULL PDF
CLICK HERE TO DOWNLOAD UPSC E-BOOKS
Study Material for UPSC General Studies Pre Cum Mains
Get The Gist 1 Year Subscription Online
Click Here to Download More Free Sample Material
<<Go Back To Main Page
Courtesy: Science Reporter